Artios Pharma, a biopharmaceutical company targeting cancers, has raised £87 million in Series D funding.

The Cambridge MedTech, aiming to realise the therapeutic power of targeting the DNA damage response in cancer, said the oversubscribed financing would enable it to expand the clinical evaluation of its lead program, alnodesertib, to enrol additional patients in each of second-line pancreatic cancer and third-line colorectal cancer.

The program was recently granted US FDA Fast Track Designation for this purpose.

The proceeds from the financing will also be used to initiate a clinical trial targeting breast cancer.